February 16 - 20, 2018 - Annual Meeting of the American Academy of Dermatology, San Diego, USA
Efficacy data on IFX-1 from the Phase 2a study in patients with severe Hidradenitis Suppurativa, not eligible for biological treatment or primary or secondary failure of biological treatment, have been accepted for the late breaking session.
Presenter:
Evangelos J. Giamarellos-Bourboulis, MD, PhD (ATTIKON University Hospital, Athens, Greece)
